


We Claim:

1. A method of treating or preventing an angiogenesis-related disorder in a patient suffering from or predisposed to such a disorder which comprises administering to the patient a therapeutically effective amount of 3-benzoylphenylacetic acid or derivative of the formula:



wherein

- R = H, C<sub>1-4</sub> (un)branched alkyl, CF<sub>3</sub>, SR<sup>4</sup>;  
Y = OR', NR''R';  
R' = H, C<sub>1-10</sub> (un)branched alkyl, (un)substituted (substitution as defined by X below), (un)substituted heterocycle (substitution as defined by X below),  
-(CH<sub>2</sub>)<sub>n</sub>Z(CH<sub>2</sub>)<sub>n</sub>A;  
n = 2-6;  
n' = 1-6;  
Z = nothing, O, C=O, OC(=O), C(=O)O, C(=O)NR<sup>3</sup>, NR<sup>3</sup>C(=O), S(O)<sub>n2</sub>,  
CHOR<sup>3</sup>, NR<sup>3</sup>;  
n<sup>2</sup> = 0-2;  
R<sup>3</sup> = H, C<sub>1-6</sub> (un)branched alkyl, (un)substituted aryl (substitution as defined by X below), (un)substituted heterocycle (substitution as defined by X below);  
A = H, OH, optionally (un)substituted aryl (substitution as defined by X below), (un)substituted heterocycle (substitution as defined by X below), -(CH<sub>2</sub>)<sub>n</sub>OR<sup>3</sup>;  
R'' = H, OH, OR';  
X and X' independently = H, F, Cl, Br, I, OR', CN, OH, S(O)<sub>n2</sub>R<sup>4</sup>, CF<sub>3</sub>, R<sup>4</sup>,  
NO<sub>2</sub>;

$R^4 = C_{1-6}$  (un)branched alkyl;

$m = 0-3$ ;

$m' = 0-5$ ; and

$W = O, H$ .

5

2. The method of Claim 1 wherein

$R = H, C_{1-2}$  alkyl;

$Y = NR'R''$ ;

$R' = H, C_{1-6}$  (un)branched alkyl,  $-(CH_2)_nZ(CH_2)_{n'}A$ ;

10  $Z = \text{nothing}, O, CHOR^3, NR^3$ ;

$R_3 = H$ ;

$A = H, OH, (\text{un})\text{substituted aryl}$  (substitution as defined by X below);

X and X' independently = H, F, Cl, Br, CN,  $CF_3$ ,  $OR'$ ,  $SR^4$ ,  $R^4$ ;

$R'' = H$ ;

15  $R^4 = C_{1-4}$  (un)branched alkyl;

$m = 0-2$ ;

$m' = 0-2$ ;

$W = H$ ;

$n = 2-4$ ; and

20  $n' = 0-3$ .

3. The method of Claim 2 wherein the 3-benzoylphenylacetic acid or derivative is selected from the group consisting of 2-Amino-3-(4-fluorobenzoyl)-phenylacetamide; 2-Amino-3-benzoyl-phenylacetamide; and  
25 2-Amino-3-(4-chlorobenzoyl)-phenylacetamide.

4. The method of Claim 1 wherein the angiogenesis-related disorder is an ophthalmic angiogenesis-related disorder.

30 5. The method of Claim 4 wherein the 3-benzoylphenylacetic acid or derivative is topically administered to the eye.

6. The method of Claim 5 wherein the therapeutically effective amount of 3-benzoylphenylacetic acid or derivative is from about 0.001 to about 4.0% (w/v).

5 7. The method of Claim 4 wherein the angiogenesis-related disorder is selected from the group consisting of exudative macular degeneration; proliferative diabetic retinopathy; ischemic retinopathy; retinopathy of prematurity; neovascular glaucoma; iritis rubeosis; corneal neovascularization; cyclitis; sickle cell retinopathy; and pterygium.

10 8. The method of Claim 1 wherein the 3-benzoylphenylacetic acid or derivative is administered orally, intravenously, in a subconjunctival injection or implant, in a sub-Tenon's injection or implant, in an intravitreal injection or implant, or in a surgical irrigating solution.

15 9. The method of Claim 1 wherein the angiogenesis-related disorder is selected from the group consisting of prostate cancer; lung cancer; breast cancer; bladder cancer; renal cancer; colon cancer; gastric cancer; pancreatic cancer; ovarian cancer; melanoma; hepatoma; sarcoma; and lymphoma.